Agendia NV withdrew its filing for a U.S. initial public offering on Friday, saying it no longer wishes to conduct the offering.
The cancer diagnostics company had filed with the Securities and Exchange Commission in late October, after having postponed an IPO plan in 2011. Agendia’s stockholders included Norgine Ventures, Athyrium Capital Management and Korys Investments.
In May, Agendia said it had enrolled 10,000 patients in its FLEX Registry, a study intended to enable the discovery of novel genomic profiles to improve precision in the management of breast cancer.
